1 research outputs found
Clinical indicators of the development of a second oral malignancy at a previously treated cancer site : early results of a longitudinal study
Oral squamous cell carcinoma (SCC) has a poor 5-year survival rate of just over
50%, largely due to a high rate of second oral malignancies (SOM) including
both recurrences and second primary tumours. Current dinicopathological
indicators for oral premalignant lesions (OPLs) at high-risk of progressing into
cancer are based on primary OPLs. Little is known whether these risk indicators
apply to OPLs at previously treated cancer sites, which are particularly difficult to
differentiate from reactive changes resulting from aggressive treatment of the
tumours.
Objective, to discover which clinicopathological indicators, if any, could
significantly predict a SOM at the previously treated cancer site at around 1 year
(8 - 16 months) after treatment of the cancer.
Method. 84 patients with oral cancer (treated with intent to cure) being followed
prospectively in the Oral Oncology/Oral Dysplasia Clinic were used in this thesis.
Three categories of data were collected: (1) demographic and habit information
(age, gender, ethnicity and tobacco habits) (2) primary tumour information
(stage, site, histology and treatment of the tumour) and (3) dinicopathological
features of post-treatment cancer site during follow up (the presence of an OPL,
size, appearance, toluidine blue (TB) staining, histopathology and treatment of
the OPLs).
Results. 18 patients (21%) have developed a SOM at the treated cancer site
(SOM group) within an average of 26 (± 14) months. Follow-up time for 66
patients who did not develop SOM (non-SOM group) was 28 (± 15) months.
Demographics, smoking habit and features of the primary oral cancer did not
predict SOM.
Of the clinicopathological features of post-treatment cancer site during follow up,
appearance, histopathology and treatment of OPLs did not predict SOM. There
was a trend in increasing size of OPLs in the SOM group (14 ± 16 mm in
diameter vs. 6 ± 5 for non-SOM group, P =0.07). However, 2 significant
predictors were found. The presence of leukoplakia at the prior cancer site was
significantly associated with SOM both at one-year post tumour treatment (72%
vs. 15% in non-SOM group, P< 0.001) and ever during follow up (83% vs.
36%, P= 0.001). Uptake of TB stain was also significantly associated with SOM
both at one-year post tumour treatment (50% vs. 11% in non-SOM group, P-
0.001) and during the entire follow-up (67% vs. 25%, P= 0.002).
Conclusion: The results showed that presence of an OPL at the previous tumour
site (regardless of its appearance and size) and TB positivity were significant risk
predictors for SOM.Dentistry, Faculty ofGraduat